Matches in Nanopublications for { ?s ?p "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP656430.RACM6yXkw8uHtA6ezPmfXnE5TvY1nQyP6rGGPrFkIaFQ4130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP656430.RACM6yXkw8uHtA6ezPmfXnE5TvY1nQyP6rGGPrFkIaFQ4130_provenance.
- NP819632.RARP-knUpu2cjCPxz-H1E5-1hv9I0bppvsdv5YNoOSqNU130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP819632.RARP-knUpu2cjCPxz-H1E5-1hv9I0bppvsdv5YNoOSqNU130_provenance.
- assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP343167.RABr7uluPJdV91cBNHqLZj93On7sTzpbMFN-79XI8kMPs130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP343167.RABr7uluPJdV91cBNHqLZj93On7sTzpbMFN-79XI8kMPs130_provenance.
- NP591812.RARHT71s_psbJ5A_nvzRttBZw90Ba7CERkRzAq6xCtTM8130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591812.RARHT71s_psbJ5A_nvzRttBZw90Ba7CERkRzAq6xCtTM8130_provenance.
- NP591813.RAdPLb0H8fKrwifCnN5xfudK8qJZaG6AHy1tssF1jieRQ130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591813.RAdPLb0H8fKrwifCnN5xfudK8qJZaG6AHy1tssF1jieRQ130_provenance.
- NP591815.RAcFnMab3LSNUw9GGH3S4wZsuNSmvbQaOSliJlapmZOD0130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591815.RAcFnMab3LSNUw9GGH3S4wZsuNSmvbQaOSliJlapmZOD0130_provenance.
- NP591814.RAMVTl3q3lWECLLhmk0V1M2Z4aVMhOUaqf3h6Glf0c1P0130_assertion description "[The proposed risk-associated genotypes are NAT2 slow acetylator (without wild-type NAT2*4 allele), CYP2E1 *1A/*1A (homozygous wild type) and homozygous null GSTM1 genotype.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP591814.RAMVTl3q3lWECLLhmk0V1M2Z4aVMhOUaqf3h6Glf0c1P0130_provenance.